Skip to content

Prostate-Specific Antigen (PSA) with Free PSA Fraction

Published: August 9, 2026Updated: August 16, 2026

This test measures the proportion of free PSA (a non-specific marker) in your blood to help assess prostate health and potential concerns like benign prostatic hyperplasia (BPH) or early prostate cancer.

Quick summary

["Understanding your free PSA ratio can help guide discussions about prostate health and next steps in diagnosis or monitoring."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
111517-9
Short code
p-tau217/AL beta42 SerPl-Rto
Synonyms
p-tau217/AL beta42 SerPl-Rto
Category
coagulation
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Ref low
0.8
Ref high
1.2
Critical range
— – 5 N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
CPT
85610
SNOMED
396252006
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Is Done

Doctors may order this test if you have symptoms like frequent urination, difficulty urinating, or if you’re at higher risk for prostate issues. It can also be used after a PSA blood test to provide more detailed information about prostate health.

What to Expect Before the Test

No special preparation is needed. You’ll have a simple blood draw, typically done in a clinic or lab. Avoid ejaculation for 2–3 days before the test if instructed by your provider.

What the Results Mean

The test compares total PSA to free PSA. A higher free PSA fraction (typically >25%) often suggests less concern for cancer, while lower ratios may warrant further evaluation. Your results will be discussed with your healthcare provider.

Common Reasons for Abnormal Results

Elevated or low free PSA ratios can indicate conditions like prostate inflammation, BPH, or early cancer. However, results alone don’t diagnose a condition—they guide further testing or follow-up.

Reference range

INR: 0.8-1.2 (warfarin: 2.0-3.0)N/A

Specimen: serum

Inform your healthcare provider if you are taking blood thinners. No special preparation required.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

This test helps differentiate between benign prostate conditions and early prostate cancer by providing a ratio that reflects the proportion of PSA bound to proteins (inactive) versus free PSA (active). It supports more precise risk assessment and treatment planning.

Short name

PSA Free Fraction Test

Frequently asked questions

Will this test show if I have prostate cancer?
No, this test alone cannot diagnose prostate cancer. It helps narrow down concerns by assessing the PSA fraction, but additional tests (like a biopsy) may be needed for confirmation.
Can I eat or drink anything before this test?
You can eat and drink normally. However, if your provider instructed otherwise (e.g., fasting for other tests), follow their guidance.
How long will I wait for my results?
Results are typically available within 1–3 business days, depending on your lab. Your healthcare provider will discuss them with you.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy